Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5184 |
ERK5-IN-1
|
ERK | MAPK |
ERK5-IN-1 是 ERK5抑制剂,IC50为 87 nM。它也抑制 LRRK2[G2019S],IC50为 26 nM。 | |||
T1842 |
XMD17-109
XMD17 109,ERK5-IN-1 |
ERK | MAPK |
XMD17-109 (ERK5-IN-1) 是一种特异性的ERK-5抑制剂,在 HEK293 细胞系中的EC50为 4.2 μM。 | |||
TP1897L1 |
JIP-1 (153-163) acetate(438567-88-5 free base)
|
JNK | MAPK |
JIP-1 (153-163) acetate(438567-88-5 free base) 是c-Jun N-末端激酶 (JNK) 的肽抑制剂,基于 JNK-interacting protein-1 (JIP-1) 的残基 153-163。以微摩尔范围内的亲和力与 JNK 结合,并抑制 p38 和 ERK。 | |||
T74374 |
ERK1/2 inhibitor 4
|
||
ERK1/2 inhibitor 5 是一种有效的ERK1/2抑制剂。丝裂原活化蛋白激酶 (MAPK) 在信号转导通路中起着极其重要的作用,而细胞外信号调节激酶 (ERK) 是MAPK 家族的成员。ERK1/2 inhibitor 5 具有研究或预防癌症、炎症或其他增殖性疾病的潜力。 | |||
T35940 |
Darinaparsin
Dimethylarsinic glutathione,Darinaparsin |
||
Darinaparsin is a dimethylated arsenic linked to glutathione. It is cytotoxic to DU145, LNCaP, and PC3 prostate cancer cells (IC50s = 5-10 µM) and patient-derived primary prostate cancer cells (IC50s = 2.5-20 µM), as well as Jurkat T cell lymphoma and L540 Hodgkin lymphoma cells (IC50s = 2.7 and 1.3 µM, respectively). [1][2] It decreases the tumor-initiating subpopulation in DU145 and PC3 cells and halts the cell cycle in the G2/M phase. Darinaparsin decreases transcription of Gli-2,... | |||
T35897 |
ASK120067
|
||
ASK120067 is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1]. In the in vitro kinase assay ASK120067 potently inhibits the EGFR L858R/T790M and EGFR T790M resistant mutants with IC50 values of 0.3 nM and 0.5 nM, respectively, as well as the EGFRexon19del sensitizing mutant (IC50= 0.5 nM). The 50 of ASK120067 against wild-type EGFR (EGFRWT... | |||
T36679 |
Rp-cAMPS sodium salt
|
||
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases[1][2][3][4][5][6]. A membrane-permeable competitive cAMP antagonist (Rp-cAMPS) that blocks PKA activation by binding to the regulatory subunits without dissociating the kinase holoenzyme also inhibits synaptic plasticity but has no effect on normal synaptic t... |